Evidence map›Paper›PMID 34326132›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2021

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.

Xiangqian Zheng, Zhengang Xu, Qinghai Ji, Minghua Ge, Feng Shi, Jianwu Qin, Feng Wang, Guang Chen, Yuan Zhang, Rui Huang and 10 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 6 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. BRAFThyroid research · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Clinical efficacy of iodine-125 (American journal of cancer research · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 3 countries.

Xiangqian ZhengDepartment of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.ORCID 0000-0001-5545-119X
Zhengang XuDepartment of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qinghai JiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Minghua GeDepartment of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Feng ShiThyroid Tumor Internal Medicine Department, Hunan Cancer Hospital, Changsha, China.
Jianwu QinDepartment of Thyroid and Neck, Henan Cancer Hospital, Henan, China.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing, China.
Guang ChenDepartment of Thyroid Surgery, The First Hospital of Jilin University, Jilin, China.
Yuan ZhangDepartment of Head and Neck Surgery, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Rui HuangDepartment of Nuclear Medicine, West China School of Medicine/West China Hospital, Sichuan University, Sichuan, China.
Jian TanDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.
Tao HuangDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0003-2130-8621
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi, China.
Zhongwei LvDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Shanghai, China.
Yansong LinDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China.
Zhuming GuoDepartment of Head and Neck Surgical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Tomoki KubotaJapan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
Takuya SuzukiJapan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
Hiroki IkezawaClinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
Ming GaoDepartment of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. gaoming68@aliyun.com.ORCID 0000-0002-0118-541X
Eisai (Japan) · JPChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University Shanghai Cancer Center · CNHenan Cancer Hospital · CNHunan Cancer Hospital · CNJiangsu Cancer Hospital · CNJilin University · CNNanjing Medical University · CNShanghai Tenth People's Hospital · CNShanxi Medical University · CNSichuan University · CNSun Yat-sen University · CNTianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University General Hospital · CNUnion Hospital · CNWuhan Union Hospital · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLenvatinib has shown efficacy in treating radioiodine-refractory differentiated thyroid cancer (RR-DTC) in the multinational phase III SELECT study; however, it has not been tested in Chinese patients with RR-DTC. PATIENTS AND

methodsChinese patients with confirmed RR-DTC (

resultsProgression-free survival was significantly longer with lenvatinib treatment [

conclusionsLenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate in Chinese patients with RR-DTC versus placebo. There were no new or unexpected toxicities. Results are consistent with those from SELECT involving patients with RR-DTC.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsChinaDouble-Blind MethodFemaleHumansIodine RadioisotopesMaleMiddle AgedPhenylurea CompoundsQuinolinesRadiation ToleranceThyroid NeoplasmsYoung AdultAntineoplastic AgentsIodine RadioisotopeslenvatinibPhenylurea CompoundsQuinolines

Identifiers

PMID34326132
PMCPMC9401493
OpenAlexW3184438309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.